QIAGEN N.V.（凯杰） - Global Leader in Sample to Insight Solutions

📢 Key Milestones (2025-2026):
   QIAGEN completed two strategic bolt-on acquisitions in 2025: Parse BioSciences (single-cell analysis, ~$225 million upfront) and Genoox (genomic data interpretation). Full-year 2025 net sales reACHed $2.09 billion with 5% CER growth. In April 2026, QIAGEN launched the QIAstat-Dx BCID GPF Plus AM panel, achieving CE-IVDR certification and expanding into bloodstream infection syndromic testing.

Company Profile (Updated April 2026)

QIAGEN N.V. is a global leader in Sample to Insight solutions, enabling customers to extract and analyze molecular information from biological samples containing DNA, RNA, and proteins. Founded in 1984 in Hilden, Germany, by scientists from Heinrich Heine University Düsseldorf, the company has evolved from a pioneer in nucleic acid purification kits to a comprehensive provider of sample technologies, assay technologies, bioinformatics, and automation solutions. QIAGEN employs approximately 5,654 people across more than 35 locations worldwide and serves over 500,000 customers in life sciences research and molecular diagnostics.

The company's legal headquarters is located in Venlo, Netherlands, while its main operational headquarters remains in Hilden, North Rhine-Westphalia, Germany. QIAGEN's shares are traded on the New York Stock Exchange (NYSE: QGEN) and the Frankfurt Stock Exchange (Prime Standard: QIA). As of April 2026, the company has a market capitalization of approximately $8.5 billion and pays a quarterly dividend with a yield of about 0.61%.

Development History:

- 1984: Founded as Diagen Institut für molekularbiologische Diagnostik GmbH in Hilden, Germany, by Dr. Metin Colpan, Karsten Henco, Dirk Lauenstein, and Prof. Dr. Detlev Riesner

- 1986: Launched first ready-to-use plasmid purification kit; established US subsidiary to enter North American market

- 1996: Reorganized as Dutch holding company QIAGEN N.V. with legal headquarters in Venlo, Netherlands; became first German biotech company listed on NASDAQ (ticker: QGEN)

- 1997: Listed on Frankfurt Stock Exchange (Neuer Markt, now Prime Standard: QIA)

- 2007: Acquired Digene Corporation for $1.6 billion, establishing leadership in HPV testing and molecular diagnostics

- 2018: Acquired STAT-Dx and launched QIAstat-Dx syndromic testing platform; entered strategic partnership with Illumina for NGS diagnostics

- 2021: Launched QIAcuity digital PCR system, becoming a major growth driver in sensitive molecular quantification

- 2023: Acquired Verogen to strengthen human identification and forensic genomics leadership

- 2024: Expanded Hilden manufacturing capacity by 20% to meet rising global demand

- 2025: Acquired Parse Biosciences and Genoox; exceeded full-year Outlook with $2.09 billion net sales; discontinued NeuMoDx product line

Core Mission: To deliver Sample to Insight solutions that transform biological samples into valuAble molecular insights, improving healthcare and life sciences research through innovative technologies in sample preparation, assay development, bioinformatics, and automation.

Growth Pillars & Strategic Focus

QIAGEN's strategy centers on five growth pillars that collectively delivered $1.49 billion CER in combined sales with 8% CER growth in 2025, and are expected to reach approximately $1.64 billion CER in 2026 (+9% CER):

QIAstat-Dx (Syndromic Testing)

An automated platform for Rapid detection of infectious diseases. Delivered strong double-digit growth throughout 2025 (+24% CER for full year, +41% CER in Q2 2025), driven by expanding installed base in hospitals and labs coupled with a growing menu of diagnostic panels. In April 2026, QIAGEN expanded into bloodstream infections with the QIAstat-Dx BCID GPF Plus AM panel, achieving CE-IVDR certification.

QuantiFERON (TB Diagnostics)

The market-leADINg blood test for latent tuberculosis infection affecting an estimated one in four people globally. QIAGEN is developing a fifth-generation test with updates planned during 2026, alongside next-generation chemistry for partner Diasorin's LIAISON QuantiFERON-TB Gold Plus II assay (U.S. launch early 2026), enabling laboratories to test up to 75% more patients per hour with 25% faster results.

QIAcuity (Digital PCR)

Nanoplate-based digital PCR system gaining significant traction in research and diagnostics, with healthy demand for associated consumables and strategic companion diagnostic development partnerships. In 2025, QIAcuity generated $15 million in diagnostic sales (Q1: $2M, Q2: $5M, Q3: $5M, Q4: $4M).

QIAGEN Digital Insights (QDI)

Bioinformatics and genomic data interpretation platform providing critical data analysis tools that complete the Sample to Insight workflow. Strengthened by the Genoox acquisition in 2025, enabling AI-driven interpretation tools and predictive modeling for pharmaceutical partners in oncology, neurology, and immunology.

Sample Technologies

Core nucleic acid extraction and purification portfolio, including silica membrane and magnetic bead technologies. Expanded into single-cell analysis through the Parse Biosciences acquisition (December 2025), adding the Evercode combinatorial barcoding platform capable of profiling millions to billions of cells without requiring specialized instruments.

Core Products & Technology Platforms

Sample Preparation

- QIAamp series: Nucleic acid purification from blood, tissue, and viral samples

- DNeasy/RNeasy: DNA and RNA isolation kits for diverse sample types

- QIAsymphony: Automated sample preparation systems for high-throughput labs

- MagAttract: Magnetic bead-based purification technologies

PCR & Real-Time PCR

- QuantiTect/QuantiFast: qPCR and RT-PCR kits for gene expression, genotyping, and gene regulation analysis

- QIAcuity: Nanoplate-based digital PCR system for absolute quantification with high precision

Instruments & Automation

- QIAstat-Dx: Syndromic testing system for infectious disease panels with integrated PCR

- QIAcube: Automated purification instruments for standardized workflows

- Rotor-Gene Q: Real-time PCR cycler with rotary technology

NGS & Bioinformatics

- GeneRead NGS panels: Targeted sequencing solutions for cancer and hereditary disease testing

- CLC Genomics Workbench: Bioinformatics analysis platform for genomic data interpretation

- QIAGEN Clinical Insight (QCI): Clinical decision support for complex genomic data

Diagnostic Assays

- QuantiFERON-TB Gold Plus: Latent tuberculosis blood test replacing 120-year-old skin tests

- therascreen: Companion diagnostic assays for oncology (e.g., PIK3CA, EGFR, KRAS)

- Artus: Molecular diagnostic assays for infectious diseases and viral load monitoring

Financial Performance

Full-Year 2025 Results

Net Sales: $2.09 billion (+6% actual rates, +5% CER), at high end of increased outlook for 4-5% CER growth

Adjusted Diluted EPS: $2.38 ($2.40 CER), ahead of outlook for ~$2.38 CER and $0.12 above initial 2025 guidance

Diluted EPS: $1.94

Adjusted Operating Income Margin: 29.5%, up 80 basis points from 2024 despite tariffs and currency headwinds

Net Income: $424.9 million (significant improvement from $83.6 million in 2024)

Total Assets: $6.30 billion

Free Cash Flow: $453.3 million

Net Debt: $55.6 million; Leverage Ratio: 0.7x

Q4 2025 Results

Net Sales: $540.4 million (+4% actual, +1% CER), exceeding outlook for steady CER results despite macroeconomic challenges and U.S. government shutdown impact

Adjusted Diluted EPS: $0.62 CER, ahead of outlook for ~$0.60 CER

2026 Outlook & Q1 Preview

- Q1 2026: Net sales growth ≥+1% CER; Adjusted diluted EPS ≥$0.54 CER

- Full-Year 2026: Net sales growth at least 5% CER; Adjusted diluted EPS at least $2.50 CER

- Growth Pillars: ~$1.64 billion CER (+9% CER), contributing the majority of expansion

- Parse Biosciences Contribution: Expected ~$40 million in 2026 sales (~2 percentage points of growth), with strong double-digit growth in subsequent years

- Q1 2026 Earnings Release Date: May 6, 2026

Company Overview

Corporate Information

Legal Name: QIAGEN N.V.

Founded: 1984

Legal Headquarters: Venlo, Netherlands

Operational Headquarters: Hilden, North Rhine-Westphalia, Germany

Stock Exchanges: NYSE (QGEN), Frankfurt Prime Standard (QIA)

Employees: ~5,654 (as of December 31, 2025)

Industry: Biotechnology / Molecular Diagnostics / Life Sciences

Customers: 500,000+ worldwide in academia, pharmaceutical R&D, clinical healthcare, and applied testing (forensics, food safety)

Dividend: Quarterly dividend; yield ~0.61% as of April 2026

Leadership & Governance (2024-2026)

CEO & Managing Director: Thierry Bernard (appointed 2020)

- Previously led QIAGEN's molecular diagnostics business; driving strategic transformation toward growth pillars and digitalization

CFO & Managing Director: Roland Sackers

- Overseeing disciplined capital allocation including $1.1 billion+ returned to shareholders ahead of schedule and strategic bolt-on acquisitions

Supervisory Board: Mark Stevenson appointed as independent member in January 2026 (former Executive Vice President and COO of Thermo Fisher Scientific); Stephen H. Rusckowski serves as Chair

Global Market Presence & Competition

Regional Revenue Distribution (2024)

- Americas: ~52% of net sales (largest market)

- EMEA: ~33% of net sales

- Asia-Pacific: ~15% of net sales (including China, Japan, Australia, and emerging markets)

Key Competitors

- Thermo Fisher Scientific: Broad life sciences and diagnostics portfolio; attempted $11 billion acquisition of QIAGEN in 2020 (rejected by shareholders)

- Roche Diagnostics: Molecular diagnostics and sequencing solutions

- Illumina: Next-generation sequencing platforms; strategic partner for NGS diagnostic kits

- Agilent Technologies: Life sciences, diagnostics, and applied chemical markets

- Bio-Rad Laboratories: Digital PCR and life science research instruments

- Standard BioTools: Single-cell analysis and mass cytometry

Competitive Advantages

- Sample to Insight Integration: Unique end-to-end workflow from sample preparation to data interpretation, creating high customer stickiness

- Recurring Revenue Model: Nearly 90% of revenue from consumables and reagents, providing predictable cash flows

- Global Scale & Reach: 35+ locations serving 500,000+ customers across 25+ countries

- Digital PCR Leadership: QIAcuity platform with nanoplate technology for precise molecular quantification

- Bioinformatics Expansion: QDI platform enhanced by Genoox acquisition, integrating AI-driven tools for clinical and research applications

- Single-Cell Innovation: Parse Biosciences' instrument-free Evercode platform enables massive-scale projects (millions to billions of cells) with broad adoption among top research institutions and pharmaceutical companies

Strategic Acquisitions (2025)

Parse Biosciences (December 2025)

- Acquisition Price: ~$225 million upfront + up to $55 million milestone payments based on multi-year targets

- Technology: Evercode combinatorial barcoding platform for instrument-free, high-throughput single-cell RNA sequencing

- Scale: Capable of profiling millions to billions of cells; GigaLab service processes up to 2.5 billion cells annually for drug and target screens

- Customers: 3,000+ labs globally, including all top 50 research institutions and top 10 pharmaceutical companies

- Intellectual Property: Exclusive license to 36 granted University of Washington patents on split-pool combinatorial barcoding

- Financial Impact: Expected ~$40 million sales contribution in 2026; dilutive by ~$0.04 to adjusted EPS in 2026, accretive from 2028

Genoox (2025)

- Specialized in genomic data interpretation and clinical reporting for next-generation sequencing

- Strengthens QDI bioinformatics capabilities, enabling development of predictive modeling and target discovery tools for pharmaceutical partners in oncology, neurology, and immunology

- Integrates with QIAGEN's existing QCI and CLC platforms to accelerate data-to-decision workflows

2026 Strategic Priorities

- Digital Transformation: Accelerate AI-driven interpretation tools and predictive modeling across QDI platform

- Single-Cell Expansion: Leverage Parse Biosciences to capture growing demand in oncology, immunology, and neuroscience research

- QuantiFERON Innovation: Launch fifth-generation TB test with enhanced workflow automation and AI-related investments for clinical decision support

- QIAstat-Dx Growth: Expand installed base and test menu for syndromic infectious disease testing in decentralized settings, including new bloodstream infection panels

- Operational Efficiency: Continue digitization and efficiency gains to fund growth investments and expand profitability toward 2028 targets

Contact Information

Global Headquarters

Netherlands (Legal): QIAGEN N.V., Venlo, Netherlands

Germany (Operational): QIAGEN GmbH, Hilden, North Rhine-Westphalia, Germany

Investor Relations

Website: www.qiagen.com

Investor Relations: corporate.qiagen.com/investors

Email: ir@qiagen.com

Stock Information

NYSE: QGEN

Frankfurt: QIA (Prime Standard)

Market Cap (April 2026): ~$8.5 billion

Dividend Yield: ~0.61%

Keywords: QIAGEN, Sample to Insight, molecular diagnostics, nucleic acid extraction, QIAstat-Dx, QuantiFERON, QIAcuity, digital PCR, QDI, bioinformatics, Parse Biosciences, Genoox, single-cell analysis, NYSE:QGEN, Frankfurt:QIA, Venlo, Hilden, Thierry Bernard, Roland Sackers, Mark Stevenson, 1984, DNA, RNA, NGS, syndromic testing, tuberculosis, HPV, companion diagnostics, life sciences, automation, magnetic bead, silica membrane, Evercode, Q-Smaragd, BCID, bloodstream infection, CE-IVDR